Exagen Inc. (XGN)
USD 5.52
(-4.83%)
USD 5.52
(-4.83%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -19.15 Million USD | 47.96% |
| 2022 | -43.11 Million USD | -65.13% |
| 2021 | -23.1 Million USD | -69.36% |
| 2020 | -13.65 Million USD | -61.58% |
| 2019 | -7.93 Million USD | -117.71% |
| 2018 | -4.35 Million USD | 43.71% |
| 2017 | -22.56 Million USD | 0.0% |
| 2015 | -13.55 Million USD | 27.08% |
| 2014 | -11.49 Million USD | -56.31% |
| 2013 | -12.05 Million USD | -6.32% |
| 2012 | -6.42 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.15 Million USD | 15.98% |
| 2024 Q1 | -2.54 Million USD | 47.64% |
| 2023 Q1 | -6.49 Million USD | 23.6% |
| 2023 Q2 | -4.43 Million USD | 31.68% |
| 2023 Q4 | -4.64 Million USD | 8.46% |
| 2023 Q3 | -5.06 Million USD | -14.19% |
| 2023 FY | - USD | 47.96% |
| 2022 Q3 | -7.47 Million USD | 39.64% |
| 2022 Q4 | -8.5 Million USD | -13.72% |
| 2022 FY | - USD | -65.13% |
| 2022 Q1 | -9.39 Million USD | -57.91% |
| 2022 Q2 | -12.38 Million USD | -31.92% |
| 2021 Q4 | -5.94 Million USD | 4.88% |
| 2021 Q3 | -6.25 Million USD | -13.12% |
| 2021 Q2 | -5.52 Million USD | -2.79% |
| 2021 FY | - USD | -69.36% |
| 2021 Q1 | -5.37 Million USD | -106.17% |
| 2020 Q3 | -3.52 Million USD | -35.41% |
| 2020 FY | - USD | -61.58% |
| 2020 Q2 | -2.6 Million USD | 47.18% |
| 2020 Q4 | -2.6 Million USD | 25.95% |
| 2020 Q1 | -4.92 Million USD | -96.88% |
| 2019 Q3 | -2.11 Million USD | 2.13% |
| 2019 Q2 | -2.16 Million USD | -33.31% |
| 2019 Q1 | -1.62 Million USD | -4256.41% |
| 2019 FY | - USD | -117.71% |
| 2019 Q4 | -2.5 Million USD | -18.25% |
| 2018 Q3 | -909 Thousand USD | 28.76% |
| 2018 Q4 | 39 Thousand USD | 104.29% |
| 2018 FY | - USD | 43.71% |
| 2018 Q2 | -1.27 Million USD | 34.29% |
| 2018 Q1 | -1.94 Million USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2015 Q2 | -3.29 Million USD | -65.54% |
| 2015 Q4 | -1.64 Million USD | -1.05% |
| 2015 FY | - USD | 27.08% |
| 2015 Q1 | -1.99 Million USD | 13.21% |
| 2015 Q3 | -1.62 Million USD | 50.67% |
| 2014 Q1 | -2.88 Million USD | -22.88% |
| 2014 Q4 | -2.29 Million USD | 30.55% |
| 2014 Q3 | -3.3 Million USD | -1.54% |
| 2014 Q2 | -3.25 Million USD | -12.79% |
| 2014 FY | - USD | -56.31% |
| 2013 Q1 | -1.8 Million USD | 0.0% |
| 2013 FY | - USD | -6.32% |
| 2013 Q3 | -1.62 Million USD | 7.27% |
| 2013 Q2 | -1.74 Million USD | 3.16% |
| 2013 Q4 | -2.34 Million USD | -44.79% |
| 2012 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bionano Genomics, Inc. | -213.6 Million USD | 91.033% |
| Prenetics Global Limited | -47.89 Million USD | 60.011% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -1035.329% |
| CareDx, Inc | -89.65 Million USD | 78.637% |
| Exact Sciences Corporation | 41.87 Million USD | 145.737% |
| Inotiv, Inc. | -26.5 Million USD | 27.741% |
| Guardant Health, Inc. | -433.3 Million USD | 95.58% |
| Biodesix, Inc. | -37.1 Million USD | 48.379% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | -670.695% |
| Precipio, Inc. | -4.31 Million USD | -343.562% |
| iSpecimen Inc. | -9.1 Million USD | -110.387% |
| Natera, Inc. | -383.27 Million USD | 95.003% |
| Aspira Women's Health Inc. | -16.49 Million USD | -16.142% |
| Standard BioTools Inc. | -54.45 Million USD | 64.829% |
| 23andMe Holding Co. | -291.87 Million USD | 93.438% |
| Castle Biosciences, Inc. | -45.02 Million USD | 57.46% |
| Personalis, Inc. | -96.8 Million USD | 80.215% |
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 83.709% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | -99.697% |
| OpGen, Inc. | -29.51 Million USD | 35.099% |
| T2 Biosystems, Inc. | -43.87 Million USD | 56.346% |
| Myriad Genetics, Inc. | -67.8 Million USD | 71.751% |
| ICON Public Limited Company | 1.63 Billion USD | 101.174% |
| NeoGenomics, Inc. | -17.6 Million USD | -8.781% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -1035.329% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 101.573% |
| RadNet, Inc. | 292.78 Million USD | 106.542% |
| MDxHealth SA | -30.46 Million USD | 37.137% |
| Psychemedics Corporation | -251 Thousand USD | -7530.677% |
| Illumina, Inc. | -608 Million USD | 96.85% |
| Check-Cap Ltd. | -17.64 Million USD | -8.522% |
| Twist Bioscience Corporation | -176.7 Million USD | 89.161% |
| DarioHealth Corp. | -53.49 Million USD | 64.196% |
| Fulgent Genetics, Inc. | -46.55 Million USD | 58.857% |
| Sera Prognostics, Inc. | -35.28 Million USD | 45.722% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | -95.742% |
| OPKO Health, Inc. | -65.51 Million USD | 70.766% |
| Medpace Holdings, Inc. | 363.15 Million USD | 105.274% |
| Neogen Corporation | 182.59 Million USD | 110.489% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | -117.383% |
| Prenetics Global Limited | -47.89 Million USD | 60.011% |
| Mainz Biomed B.V. | -25.01 Million USD | 23.422% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -151.045% |
| Trinity Biotech plc | -24.09 Million USD | 20.52% |
| Neuronetics, Inc. | -22.75 Million USD | 15.844% |
| Sotera Health Company | 514.14 Million USD | 103.725% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -151.045% |